Results 51 to 60 of about 7,681 (165)

Demographic information for ENLIGHTEN maraviroc DOT study participants.

open access: yes, 2023
Demographic information for ENLIGHTEN maraviroc DOT study participants.
Elias P. Rosen (1430320)   +8 more
core   +1 more source

Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group.

open access: yes, 2016
INTRODUCTION: Limited data is available regarding the hepatic safety of maraviroc in patients co-infected with HIV and HCV and/or HBV. Our objective was to compare the hepatic safety profile and fibrosis progression in HIV-mono-infected patients and co ...
Moreno, S   +9 more
core   +2 more sources

Longer Asthma Duration Is Associated With Elevated Non‐T2 Sputum Biomarkers and Reduced T2 Inflammation in Severe Asthma

open access: yesAllergy, Volume 81, Issue 9, Page 3286-3299, September 2026.
Longer asthma duration is associated with increased airway non‐T2 inflammation and reduced airway and systemic T2 inflammation. Sputum CXCL9 is independently associated with duration and may predict a reduced poor response to anti‐IL‐4Rα therapy. Airway sampling and combined T2 and non‐T2 targeted strategies may be needed in long‐standing asthma. CXCL9,
Freda Yang   +298 more
wiley   +1 more source

Activity of Maraviroc in MDM.

open access: yes, 2013
In vitro efficacy of Maraviroc in MDM cultures. The bars represents the percentage of viral inhibition (p24 production pg/ml) in presence of Maraviroc, AMD3100 and AZT at different concentrations, considering the untreated as 100. Mean values of at least
Patrizia Saccomandi (431861)   +11 more
core   +1 more source

Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc

open access: yesHIV/AIDS: Research and Palliative Care, 2010
Eva Poveda, Vincent SorianoDepartment of Infectious Diseases, Hospital Carlos III, Madrid, SpainAbstract: Maraviroc is the first CCR5 antagonist approved for the treatment of HIV-1 infection.
Eva Poveda, Vincent Soriano
doaj  

Drug Resistance in Multiple Myeloma: Tumor‐Intrinsic Mechanisms and the Bone Marrow Microenvironment

open access: yesCell Biochemistry and Function, Volume 44, Issue 8, August 2026.
ABSTRACT Multiple myeloma (MM) is a malignant plasma cell disorder, and despite substantial improvements in prognosis achieved through chemotherapy, immunotherapy, and autologous stem cell transplantation, most patients ultimately develop relapsed or refractory disease. Drug resistance (DR) is increasingly recognized as a dynamically evolving ecosystem
Yixuan Chen   +3 more
wiley   +1 more source

Antiretroviral treatment classes used with maraviroc.

open access: yes, 2019
Antiretroviral treatment classes used with maraviroc.
Maurizio Zazzi (146810)   +11 more
core   +1 more source

Emerging insights into CC and CXC chemokines and their receptors in Mycobacterium tuberculosis infection

open access: yesFEBS Open Bio, Volume 16, Issue 7, Page 1244-1258, July 2026.
The dual roles of CC and CXC chemokines in distinguishing active, latent, and subclinical tuberculosis were reviewed, along with an evaluation of their potential as diagnostic biomarkers and therapeutic targets to advance precision medicine in tuberculosis management. The graphical abstract was generated with AI assistance (Gemini 3.0).
Xuying Yin, Dangsheng Xiao, Jiezuan Yang
wiley   +1 more source

A Microbial Lipid‐ATP Synthase Axis Fuels NK Cell Antitumor Activity

open access: yesAdvanced Science, Volume 13, Issue 39, 13 July 2026.
This study focuses on the mechanism by which gut microbiota‐derived outer membrane vesicles (OMVs) regulate NK cell antitumor activity. B. intestinalis is identified to decrease extra‐intestinal tumor growth via its OMVs enriched in sphingosine (SP).
Kaiyuan Yu   +16 more
wiley   +1 more source

Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc

open access: yes, 2009
Sustained inhibition of HIV-1, the goal of antiretroviral therapy, is often impeded by the emergence of viral drug resistance. For patients infected with HIV-1 resistant to conventional drugs from the viral reverse transcriptase and protease inhibitor ...
Olga Latinovic   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy